The shingles vaccine market revenue is expected to grow at a robust rate over the forecast period. Shingles, also known as herpes zoster, is a viral infection that affects the cranial nerves that originate in the brain. It is caused by the varicella zoster virus, the same virus that also cases chicken pox. The virus can stay dormant for many years in the human body. Therefore, anyone who has had chicken pox in the past is at the risk of developing shingles. According to the Center for Disease Control and Prevention (CDC), there are an estimated one million cases of shingles reported every year in the U.S. Moreover, CDC states that around one in every three people in the U.S. will develop shingles in their lifetime. The risk of shingles increases with age, with most cases reported among people over 40 years old. This is mainly due to weakening of the immune system on account of increased stress and inadequate intake of essential nutrients to keep immunity strong.
Symptoms include skin rashes, nerve pain, vision loss, chills, upset stomach, muscle weakness, skin infection, and scarring. Treatment for shingles includes antiviral medication—acyclovir, valacyclovir, and famciclovir. These medicines help shorten the length and alleviate the severity of the illness. Further, analgesics may help relieve the pain.
Shingles Vaccine Market Dynamics
There is a safe and effective vaccines available for preventing shingles. The Zostavax vaccine licensed by Merck & Co., Inc. in 2006 is an effective vaccine against shingles. The vaccine is intended for use in population over 50 years of age. The trials of the Zostavax vaccine demonstrated that the vaccine was 64% effective in people aged 60 to 69 years. The effectiveness reduces with increasing age i.e. to 41% for the 70–79 age group, and 18% for those 80 years of age and older. The vaccine was launched in the India market in February 2016, at half the price of the U.S. market. Zostavax, among the only shingles vaccine in the market, recorded sales of US$ 749 million in 2015.
In October 2016, GlaxoSmithKline (GSK)—a global leader in vaccines market—filed for U.S. FDA approval for its shingles vaccine, Shingrix. Shingrix has demonstrated better outcomes than Zostavax in its clinical trials. The vaccine was 90% efficacious in people over 70 years of age. The overall effectiveness of the vaccine is found to be 97%. Its higher effectiveness even among elder group of people is projected to increase its adoption across the globe. The impressive trail results would put Shingrix in a strong competitive position in the global market, currently monopolized by Zostavax. The company is reported to have filed for regulatory approvals in the Europe and Canada markets in 2016, followed by Japan in 2017. It is estimated that the sales of Shingrix would reach US$ 1 billion by 2021.
Shingles vaccines market is witnessing rapid influx of newer and expensive products. The industry is consolidated in nature however, new entrants are expected to emerge in the near future.
Shingles Vaccine Market Regional Analysis
North America and Europe are expected to collectively account for a major share of the market between 2016 and 2024. North America market growth is primarily driven by rising demand in the U.S., while the market in Europe is expected to be driven by increased therapeutic demand from European Union.
Asia Pacific shingles vaccine market is expected to witness highest growth over the forecast period. There is a wide addressable market that needs to be capitalized upon in the region especially in China and India. Active marketing and differential pricing would help companies to strengthen their market presence in Asia Pacific.
Shingles Vaccine Market Opportunity
Prevalence of shingles is increasing across the globe, fuelled mainly by increasing aging population. However, high cost of vaccines is limiting vaccination drive in emerging economies, characterized by inadequate insurance coverage. The major concern among healthcare experts is reduction in postherpetic neuralgia from the shingles vaccine. Zostavax has been successful to a certain extent in reducing postherpetic neuralgia due to the effect of the vaccine on reducing risk of developing herpes zoster. Better outcomes of Shingrix would be a boon for highly lucrative global shingles vaccines market.
Major institutes are focused on R&D on shingles vaccine. For instance, in August 2019, a team of researchers from Centre de research du Centre hospitalier de l'Université de Québec and the Université Laval, Québec, found that the Shingrix vaccine was cost-effective for adults age 60 years and above and likely more cost-effective than Zostavax.
Approval and launch of mew shingles vaccines is expected to boost the market growth. For instance, in May 2019, the National Medical Products Administration (NMPA) of China approved Shingrix, developed by GlaxoSmithKline plc., for the prevention of shingles in adults aged 50 years or older.
Moreover, in March 2018, the European Commission and the Japanese Ministry of Health, Labor and Welfare approved Shingrix for the prevention of shingles and post-herpetic neuralgia in adults aged 50 years or older.
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.[email protected]
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.